Trevena

Historical price data

Trevena's mission is to develop safer and more effective CNS therapies by exploiting biased ligand signaling at G protein-coupled receptors (GPCRs). Its primary achievement is the 2020 FDA approval of OLINVYK, a biased mu-opioid receptor agonist for acute pain, though commercial uptake has been limited. The company's current strategy is to advance its early-stage pipeline, including TRV045 for neuropathic pain and epilepsy, while navigating severe financial constraints and seeking strategic alternatives to sustain operations.

A drug discovery platform focused on designing biased ligands that selectively activate therapeutic G protein signaling pathways while minimizing adverse-effect-linked β-arrestin pathways within G protein-coupled receptors (GPCRs).

Trevena faces intense competition in every therapeutic area: generic IV opioids in acute pain, established neuromodulators and CGRP inhibitors in migraine/pain, and approved therapies for OUD. Its primary disadvantage is a severe lack of capital compared to deep-pocketed competitors, limiting its ability to advance development or commercialize effectively.